Page 23 - Read Online

11. Pons F, Varela M, Llovet JM. Staging systems in hepatocellular 36. Strazzabosco M, Fabris L. Notch signaling in hepatocellular carcinoma:
carcinoma. HPB (Oxford) 2005;7:35-41. guilty in association! Gastroenterology 2012;143:1430-4.
12. McGlynn KA, London WT. The global epidemiology of hepatocellular 37. O’Neil J, Grim J, Strack P, Rao S, Tibbitts D, Winter C, Hardwick J,
carcinoma: present and future. Clin Liver Dis 2011;15:223-43, vii. Welcker M, Meijerink JP, Pieters R, Draetta G, Sears R, Clurman BE,
13. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, Look AT. FBW7 mutations in leukemic cells mediate NOTCH pathway
de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, activation and resistance to gamma-secretase inhibitors. J Exp Med
Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, 2007;204:1813-24.
Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; 38. Thompson BJ, Buonamici S, Sulis ML, Palomero T, Vilimas T, Basso G,
SHARP Investigators Study Group. Sorafenib in advanced hepatocellular Ferrando A, Aifantis I. The SCFFBW7 ubiquitin ligase complex as a
carcinoma. N Engl J Med 2008;359:378-90. tumor suppressor in T cell leukemia. J Exp Med 2007;204:1825-35.
14. Villanueva A, Llovet JM. Targeted therapies for hepatocellular 39. D’Souza B, Meloty-Kapella L, Weinmaster G. Canonical and
carcinoma. Gastroenterology 2011;140:1410-26. non-canonical Notch ligands. Curr Top Dev Biol 2010;92:73-129.
15. Nakanishi K, Sakamoto M, Yamasaki S, Todo S, Hirohashi S. Akt 40. Boulter L, Govaere O, Bird TG, Radulescu S, Ramachandran P,
phosphorylation is a risk factor for early disease recurrence and poor Pellicoro A, Ridgway RA, Seo SS, Spee B, Van Rooijen N, Sansom OJ,
prognosis in hepatocellular carcinoma. Cancer 2005;103:307-12. Iredale JP, Lowell S, Roskams T, Forbes SJ. Macrophage-derived Wnt
16. Vanhaesebroeck B, Stephens L, Hawkins P. PI3K signalling: the path to opposes Notch signaling to specify hepatic progenitor cell fate in chronic
discovery and understanding. Nat Rev Mol Cell Biol 2012;13:195-203. liver disease. Nat Med 2012;18:572-9.
17. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT 41. Viatour P, Ehmer U, Saddic LA, Dorrell C, Andersen JB, Lin C,
pathway in human cancer. Nat Rev Cancer 2002;2:489-501. Zmoos AF, Mazur PK, Schaffer BE, Ostermeier A, Vogel H,
18. Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S, Hoshida Y, Sylvester KG, Thorgeirsson SS, Grompe M, Sage J. Notch signaling
Villanueva A, Minguez B, Newell P, Tsai HW, Barretina J, Thung S, inhibits hepatocellular carcinoma following inactivation of the RB
Ward SC, Bruix J, Mazzaferro V, Schwartz M, Friedman SL, Llovet JM. pathway. J Exp Med 2011;208:1963-76.
Wnt-pathway activation in two molecular classes of hepatocellular 42. Wu G, Wilson G, George J, Qiao L. Modulation of Notch signaling as a
carcinoma and experimental modulation by sorafenib. Clin Cancer Res therapeutic approach for liver cancer. Curr Gene Ther 2015;15:171-81.
2012;18:4997-5007. 43. Oda T, Elkahloun AG, Pike BL, Okajima K, Krantz ID, Genin A,
19. Ranganathan P, Weaver KL, Capobianco AJ. Notch signalling in solid Piccoli DA, Meltzer PS, Spinner NB, Collins FS, Chandrasekharappa SC.
tumours: a little bit of everything but not all the time. Nat Rev Cancer Mutations in the human Jagged1 gene are responsible for Alagille
2011;11:338-51. syndrome. Nat Genet 1997;16:235-42.
20. Razumilava N, Gores GJ. Notch-driven carcinogenesis: the merging of 44. Li PH, Shu SG, Yang CH, Lo FC, Wen MC, Chi CS. Alagille syndrome
hepatocellular cancer and cholangiocarcinoma into a common molecular with interstitial 20p deletion derived from maternal ins (7;20). Am J Med
liver cancer subtype. J Hepatol 2013;58:1244-5. Genet 1996;63:537-41.
21. Rose SL, Kunnimalaiyaan M, Drenzek J, Seiler N. Notch 1 signaling is 45. Li L, Krantz ID, Deng Y, Genin A, Banta AB, Collins CC, Qi M,
active in ovarian cancer. Gynecol Oncol 2010;117:130-3. Trask BJ, Kuo WL, Cochran J, Costa T, Pierpont ME, Rand EB,
22. Austin J, Kimble J. glp-1 is required in the germ line for regulation Piccoli DA, Hood L, Spinner NB. Alagille syndrome is caused by
of the decision between mitosis and meiosis in C. elegans. Cell mutations in human Jagged1, which encodes a ligand for Notch1. Nat
1987;51:589-99. Genet 1997;16:243-51.
23. Cabrera CV. The generation of cell diversity during early neurogenesis 46. McDaniell R, Warthen DM, Sanchez-Lara PA, Pai A, Krantz ID,
in Drosophila. Development 1992;115:893-901. Piccoli DA, Spinner NB. NOTCH2 mutations cause Alagille syndrome,
24. Coffman C, Harris W, Kintner C. Xotch, the Xenopus homolog of a heterogeneous disorder of the notch signaling pathway. Am J Hum
Drosophila notch. Science 1990;249:1438-41. Genet 2006;79:169-73.
25. Ellisen LW, Bird J, West DC, Soreng AL, Reynolds TC, Smith SD, 47. Fausto N, Campbell JS, Riehle KJ. Liver regeneration. J Hepatol
Sklar J. TAN-1, the human homolog of the Drosophila notch gene, is 2012;57:692-4.
broken by chromosomal translocations in T lymphoblastic neoplasms. 48. Riehle KJ, Dan YY, Campbell JS, Fausto N. New concepts in liver
Cell 1991;66:649-61. regeneration. J Gastroenterol Hepatol 2011;26 Suppl 1:203-12.
26. Kunnimalaiyaan M, Chen H. Tumor suppressor role of Notch-1 signaling 49. Michalopoulos GK. Liver regeneration: alternative epithelial pathways.
in neuroendocrine tumors. Oncologist 2007;12:535-42. Int J Biochem Cell Biol 2011;43:173-9.
27. Priess JR, Schnabel H, Schnabel R. The glp-1 locus and cellular 50. Fiorotto R, Raizner A, Morell CM, Torsello B, Scirpo R, Fabris L,
interactions in early C. elegans embryos. Cell 1987;51:601-11. Spirli C, Strazzabosco M. Notch signaling regulates tubular
28. Yamamoto S, Schulze KL, Bellen HJ. Introduction to Notch signaling. morphogenesis during repair from biliary damage in mice. J Hepatol
Methods Mol Biol 2014;1187:1-14. 2013;59:124-30.
29. Morell CM, Strazzabosco M. Notch signaling and new therapeutic 51. Morell CM, Fiorotto R, Fabris L, Strazzabosco M. Notch signalling
options in liver disease. J Hepatol 2014;60:885-90. beyond liver development: emerging concepts in liver repair and
30. Mumm JS, Kopan R. Notch signaling: from the outside in. Dev Biol oncogenesis. Clin Res Hepatol Gastroenterol 2013;37:447-54.
2000;228:151-65. 52. Tanimizu N, Miyajima A. Notch signaling controls hepatoblast
31. Andersson ER, Lendahl U. Therapeutic modulation of Notch differentiation by altering the expression of liver-enriched transcription
signalling – are we there yet? Nat Rev Drug Discov 2014;13:357-78. factors. J Cell Sci 2004;117:3165-74.
32. Allenspach EJ, Maillard I, Aster JC, Pear WS. Notch signaling in cancer. 53. Chen Y, Choi SS, Michelotti GA, Chan IS, Swiderska-Syn M, Karaca GF,
Cancer Biol Ther 2002;1:466-76. Xie G, Moylan CA, Garibaldi F, Premont R, Suliman HB, Piantadosi CA,
33. Fortini ME. Notch signaling: the core pathway and its posttranslational Diehl AM. Hedgehog controls hepatic stellate cell fate by regulating
regulation. Dev Cell 2009;16:633-47. metabolism. Gastroenterology 2012;143:1319-29.e1.
34. Geisler F, Strazzabosco M. Emerging roles of Notch signaling in liver 54. Xie G, Karaca G, Swiderska-Syn M, Michelotti GA, Krüger L,
disease. Hepatology 2015;61:382-92. Chen Y, Premont RT, Choi SS, Diehl AM. Cross-talk between Notch
35. Gridley T. Notch signaling and inherited disease syndromes. Hum Mol and Hedgehog regulates hepatic stellate cell fate in mice. Hepatology
Genet 2003;12:R9-13. 2013;58:1801-13.

16 Hepatoma Research | Volume 1 | Issue 1 | April 15, 2015